Bonura Angela, Colombo Paolo
Istituto di Biomedicina ed Immunologia Molecolare "Alberto Monroy" del Consiglio Nazionale delle Ricerche, Palermo, Italy.
Inflamm Allergy Drug Targets. 2009 Jun;8(2):104-9. doi: 10.2174/187152809788462608.
Allergen-specific immunotherapy was introduced into clinical practice at the beginning of the 20(th) century and its efficacy in the treatment of seasonal allergic rhinitis has been confirmed in many clinical studies which have shown that it can prevent the onset of new sensitizations to different allergens and reduces the development of asthma in patients with allergic rhinitis. Progress in molecular cloning and characterization of allergens have made it possible to produce single recombinant allergens whose immunological properties have been tested in vitro and in vivo and have demonstrated that they retain properties resembling their natural counterpart. Several rational approaches are being developed to improve the efficacy of SIT by reducing immunoglobulin IgE-mediated adverse reactions. Some of these molecules have been tested in the clinic, demonstrating the feasibility of using biotechnology-derived products as new standardized, improved and safer therapeutic compositions.
变应原特异性免疫疗法于20世纪初被引入临床实践，其在治疗季节性变应性鼻炎方面的疗效已在许多临床研究中得到证实，这些研究表明它可以预防对不同变应原产生新的致敏反应，并减少变应性鼻炎患者哮喘的发生。变应原分子克隆和特性鉴定方面的进展使得生产单一重组变应原成为可能，其免疫特性已在体外和体内进行了测试，并证明它们保留了与其天然对应物相似的特性。目前正在开发几种合理的方法，通过减少免疫球蛋白IgE介导的不良反应来提高特异性免疫疗法的疗效。其中一些分子已在临床上进行了测试，证明了使用生物技术衍生产品作为新的标准化、改良和更安全治疗组合物的可行性。
